Should I buy or sell Oncternal Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ONCT shares. View ONCT analyst ratings or view top-rated stocks .

What is Oncternal Therapeutics' stock price target for 2024?

3 brokerages have issued 12-month price targets for Oncternal Therapeutics' stock. Their ONCT share price targets range from $26.00 to $40.00. On average, they expect the company's stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 256.1% from the stock's current price. View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts .

How have ONCT shares performed in 2024?

Oncternal Therapeutics' stock was trading at $10.7240 at the start of the year. Since then, ONCT shares have decreased by 17.9% and is now trading at $8.80. View the best growth stocks for 2024 here .

When is Oncternal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ONCT earnings forecast .

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) released its earnings results on Thursday, March, 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by $0.02. The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.17 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 95.87% and a negative net margin of 5,029.17%. During the same period in the previous year, the business posted ($4.00) earnings per share.

When did Oncternal Therapeutics' stock split?

Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK) , NVIDIA (NVDA) , OPKO Health (OPK) , Advanced Micro Devices (AMD) , QUALCOMM (QCOM) , Avadel Pharmaceuticals (AVDL) , Aldeyra Therapeutics (ALDX) , Boeing (BA) , CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX) .

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free ONCT Stock Alerts

$8.80

-0.60 (-6.38%)

(As of 04/15/2024 ET)

Compare

Today's Range: $8.69
▼
$9.36
50-Day Range: $7.80
▼
$10.15
52-Week Range: $5.57
▼
$13.14

Volume: 9,220 shs
Average Volume: 12,907 shs
Market Capitalization: $23.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get Oncternal Therapeutics alerts:

Oncternal Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 256.1% Upside
$31.33 Price Target
Short Interest: Healthy
0.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.07
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$92,736 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($12.03) to ($11.48) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

447th out of 929 stocks

Pharmaceutical Preparations Industry

200th out of 422 stocks

3.3

Analyst's Opinion

Consensus Rating
Oncternal Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Oncternal Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.63% of the float of Oncternal Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Oncternal Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oncternal Therapeutics has recently increased by 11.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Oncternal Therapeutics does not currently pay a dividend.
Dividend Growth
Oncternal Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONCT.

2.8

News and Social Media Coverage

News Sentiment
Oncternal Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Oncternal Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Oncternal Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncternal Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,736.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of Oncternal Therapeutics is held by insiders.
Percentage Held by Institutions
Only 16.05% of the stock of Oncternal Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Oncternal Therapeutics are expected to grow in the coming year, from ($12.03) to ($11.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oncternal Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncternal Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncternal Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

ONCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONCT Stock News Headlines

April 11, 2024 | insidertrades.com

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in Stock

April 2, 2024 | insidertrades.com

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 Shares

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 16, 2024 | americanbankingnews.com

Oncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $28.00 by Analysts at HC Wainwright

April 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalysts

April 14, 2024 | insidermonkey.com

5 Buy-Rated Stocks with Latest Insider Purchases

April 12, 2024 | americanbankingnews.com

Insider Buying: Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Buys 3,086 Shares of Stock

April 11, 2024 | finance.yahoo.com

AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 15, 2024 | globenewswire.com

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

March 13, 2024 | markets.businessinsider.com

Northland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)

March 10, 2024 | finance.yahoo.com

Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

March 8, 2024 | finance.yahoo.com

Q4 2023 Oncternal Therapeutics Inc Earnings Call

March 8, 2024 | msn.com

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript

March 8, 2024 | benzinga.com

Oncternal Therapeutics's Earnings: A Preview

March 7, 2024 | msn.com

ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

March 7, 2024 | benzinga.com

Recap: Oncternal Therapeutics Q4 Earnings

March 7, 2024 | washingtonpost.com

Oncternal Therapeutics: Q4 Earnings Snapshot

March 7, 2024 | globenewswire.com

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

March 6, 2024 | markets.businessinsider.com

Oncternal Therapeutics earnings: here's what to expect

February 29, 2024 | globenewswire.com

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

February 25, 2024 | finance.yahoo.com

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

February 6, 2024 | finance.yahoo.com

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 3, 2024 | morningstar.com

Oncternal Therapeutics Inc ONCT

January 30, 2024 | ca.finance.yahoo.com

ONCT Jul 2024 7.500 call

January 30, 2024 | ca.finance.yahoo.com

ONCT Apr 2024 2.500 call

January 8, 2024 | finance.yahoo.com

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

See More Headlines

Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ONCT
CUSIP: N/A
CIK: 1260990
Web: www.oncternal.com
Phone: (858) 434-1113
Fax: 901-844-8075
Employees: 27
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.33
High Stock Price Target: $40.00
Low Stock Price Target: $26.00
Potential Upside/Downside: +263.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($13.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,480,000.00
Net Margins: -5,029.17%
Pretax Margin: -5,029.17%
Return on Equity: -95.87%
Return on Assets: -83.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.94
Quick Ratio: 6.94

Sales & Book Value

Annual Sales: $790,000.00
Price / Sales: 29.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.19 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 2,690,000
Free Float: 2,474,000
Market Cap: $23.67 million
Optionable: Optionable
Beta: 1.26

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. James B. Breitmeyer M.D. (Age 70)
Ph.D., President, CEO & Director
Comp: $814.67k
Dr. Salim Yazji M.D. (Age 55)
Chief Medical Officer
Comp: $549.21k
Mr. Richard G. Vincent CPA (Age 60)
CFO & Treasurer
Comp: $524.48k
Dr. Rajesh Krishnan Ph.D. (Age 50)
Chief Technical & Scientific Officer
Mr. Chase C. Leavitt (Age 42)
General Counsel & Secretary
Mr. Pablo Urbaneja
Senior Vice President of Corporate Development
Anita Wiseth
Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ONCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncternal Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ONCT shares.
View ONCT analyst ratings or view top-rated stocks.
What is Oncternal Therapeutics' stock price target for 2024?: 3 brokerages have issued 12-month price targets for Oncternal Therapeutics' stock. Their ONCT share price targets range from $26.00 to $40.00. On average, they expect the company's stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 256.1% from the stock's current price.
View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts.
How have ONCT shares performed in 2024?: Oncternal Therapeutics' stock was trading at $10.7240 at the start of the year. Since then, ONCT shares have decreased by 17.9% and is now trading at $8.80.
View the best growth stocks for 2024 here.
When is Oncternal Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ONCT earnings forecast.

How were Oncternal Therapeutics' earnings last quarter?: Oncternal Therapeutics, Inc. (NASDAQ:ONCT) released its earnings results on Thursday, March, 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by $0.02. The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.17 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 95.87% and a negative net margin of 5,029.17%. During the same period in the previous year, the business posted ($4.00) earnings per share.
When did Oncternal Therapeutics' stock split?: Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Oncternal Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).
How do I buy shares of Oncternal Therapeutics?: Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Oncternal Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

ONCT Stock Price History

ONCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ONCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™